Clinical Trials Logo

Clinical Trial Summary

Penile squamous cell carcinoma (PSCC) is relatively rare but exhibits higher incidences in less developed countries. PSCC is a highly aggressive malignancy characterized by early spread. Pembrolizumab has recently been FDA-approved for the treatment of melanoma but will serve as the investigational agent for this penile cancer study.


Clinical Trial Description

This is a multicenter trial to evaluate Pembrolizumab for patients with advanced penile squamous cell carcinoma following prior chemotherapy. Participating institutions are the University of Alabama at Birmingham (coordinating center), M.D. Anderson Cancer Center, University of Michigan, University of Minnesota, and Emory University. Patients will receive intravenous Pembrolizumab every 3 weeks and undergo a clinical exam. Radiographic scans will be done at baseline and every 9 weeks. Therapy will continue until disease progression or there are intolerable toxicities. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02837042
Study type Interventional
Source University of Alabama at Birmingham
Contact
Status Terminated
Phase Phase 2
Start date October 2016
Completion date October 2019

See also
  Status Clinical Trial Phase
Completed NCT01807546 - Oral Rigosertib for Squamous Cell Carcinoma Phase 2
Recruiting NCT03774901 - Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma Phase 2
Not yet recruiting NCT06353906 - Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer Phase 2
Active, not recruiting NCT02496208 - Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Phase 1
Active, not recruiting NCT02834013 - Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Phase 2
Completed NCT06068998 - Molecular Characterization of Penile Cancers in Developing Countries
Recruiting NCT03943602 - Cabozantinib in Patients With Advanced Penile Squamous Cell Carcinoma (PSCC) (CaboPen) Phase 2